An Overview of the Therapeutic Development of Cholangiocarcinoma with Special Emphasis on Targeted and Biologic Therapies
Purpose of Review Cholangiocarcinoma remains difficult to treat with a poor prognosis. Nevertheless, the treatment landscape is rapidly evolving to include chemotherapy, immunotherapy, and targeted therapies. This paper will summarize recent developments in targeted therapies. Recent Findings G...
Saved in:
Published in | Current hepatology reports Vol. 22; no. 3; pp. 95 - 107 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer US
28.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: |
Purpose of Review
Cholangiocarcinoma remains difficult to treat with a poor prognosis. Nevertheless, the treatment landscape is rapidly evolving to include chemotherapy, immunotherapy, and targeted therapies. This paper will summarize recent developments in targeted therapies.
Recent Findings
Gemcitabine/cisplatin plus durvalumab or pembrolizumab is the standard first-line treatment for patients with advanced cholangiocarcinoma. Multiple alterations have been identified with corresponding approved targeted agents, including fibroblast growth factor receptor inhibitors pemigatinib, infigratinib, and futibatinib; the isocitrate dehydrogenase 1 inhibitor ivosidenib; and the inhibitors of encoded kinases of
NTRK1-3
entrectinib and larotrectinib. In tumors with microsatellite instability or deficient mismatch repair, pembrolizumab is approved. Dabrafenib and trametinib also received tumor agnostic approval for BRAF V600E mutations. Additional emerging targets include HER2 and DNA repair pathways.
Summary
Multiple targeted therapies are currently approved in the treatment of advanced cholangiocarcinoma, and many more molecular alterations or pathways have been identified as promising therapeutic targets. |
---|---|
ISSN: | 2195-9595 2195-9595 |
DOI: | 10.1007/s11901-023-00607-6 |